[Pharmacokinetics of arbekacin in dogs. II. The distribution of arbekacin in tissues].
A new aminoglycoside antibiotic, arbekacin (HBK) was intramuscularly and intravenously administered to Beagle dogs at a dose of 10 mg/kg to study its distribution into various tissues. The results obtained are summarized as follows. Biological half-lives of HBK in serum after intramuscular and intravenous injection were 1.15 hours and 1.00 hour after administration, respectively. These half-lives were similar to the results obtained in previous studies. Maximum concentrations of HBK in tissues and biological fluids after intramuscular injection were the highest in kidney followed by vagina, serum, urinary bladder, uterus, ovarium, lung, parotid gland, trachea, tonsil, gall bladder, pericardiac fluid, thymus, muscle, heart, liver, mandibular gland, bile, aqueous humor, pancreas, cerebrospinal fluid and brain, in this order. Maximum concentrations were found at 4 hours in trachea, aqueous humor and cerebrospinal fluid, and at 2 hours in pericardiac fluid. In other tissues and biological fluids, they were obtained at 0.5-1 hour. Maximum concentrations in tissues and biological fluids after 1 hour intravenous injection were the highest in kidney followed by serum, ovarium, vagina, lung, parotid gland, urinary bladder, uterus, spleen, thymus, pericardiac fluid, gall bladder, trachea, tonsil, heart, liver, pancreas, muscle, mandibular gland, bile, aqueous humor, cerebrospinal fluid and brain in this order. Maximum concentrations were found at 4 hours in trachea, cerebrospinal fluid and bile, and at 2 hours in pericardiac fluid. In other tissues and biological fluids, they were obtained at the end of the infusion. Maximum concentrations in these biological fluids after both intramuscular and intravenous injection were similar to serum concentrations except kidney, trachea, and other biological fluids.(ABSTRACT TRUNCATED AT 250 WORDS)
D000617:Aminoglycosides / Q000008:administration & dosage / Q000378:metabolism; D000818:Animals; D000900:Anti-Bacterial Agents; D003982:Dibekacin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D004285:Dogs; D005260:Female; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007612:Kanamycin / Q000031:analogs & derivatives*; D007700:Kinetics; D014018:Tissue Distribution
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003982:Dibekacin; D007612:Kanamycin; C031986:arbekacin